Proportion of secondary bacterial infections among the SARS-COV-2 patients admitted in the selected health facilities in Mombasa and Nairobi counties in Kenya

Ali Abdi Adan; Joseph Juma; Oscar Donde; Jared Otieno Ogolla

doi:10.18203/2394-6040.ijcmph20243269

Authors

Ali Abdi Adan Department of Community Health, School of Public Health, Thika, Kenya
Joseph Juma Department of Community Health, School of Public Health, Thika, Kenya
Oscar Donde Department of Environmental Science, Faculty of Environment and Resources Development, Egerton, Kenya
Jared Otieno Ogolla Department of Environmental Science, Faculty of Environment and Resources Development, Egerton, Kenya

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20243269

Keywords:

SARS, SARS-COV-2, Secondary bacterial infections, Severe acute respiratory syndrome

Abstract

Background: There is still scarcity of evidence on proportion of secondary bacterial infections among SARS-COV-2 patients in Kenya. This study therefore sought to determine the proportion of secondary bacterial infections among SARS-COV-2 patients in ICUs in the selected health facilities in Mombasa and Nairobi Counties.

Methods: The retrospective cross-sectional sampled the records of 385 SARS-COV-2 patients admitted and administered antibiotics during treatment in the intensive care units (ICU) in the six health facilities that acted as isolation and treatment centers for SARS-COV-2 patients between 13^th March 2020 and 31^st December 2021. The research team reviewed the medical records of the SARS-COV-2 positive patients and extracted the patient demographic data, medical history, underlying co-morbidities, clinical symptoms, laboratory findings, management and treatment measures and antimicrobial susceptibility tests.

Results: 47.3% of the patients in the study had secondary bacterial infections. Significant majority of patients of these patients were smokers (n=158, 86.8%, p≤0.05), had very high fever at admission in the ICU (n=139, 76.4%, p=0.033) and were administered iron supplement during the hospital stay (n=125, 68.7%, p=0.027).

Conclusions: SARS-COV-2 patients who smoke, report high fever at admission in the ICU and given iron supplement during their stay in the health facility tend to have a high prevalence of secondary bacterial infections.

Metrics

Metrics Loading ...

References

Nedel W, Da Silveira F, Da Silva CF, Lisboa T. Bacterial infection in coronavirus disease 2019 patients: co-infection, super-infection and how it impacts on antimicrobial use. Curr Opin Crit Care. 2022;28(5):463.

Fu Y, Yang Q, Xu M, Kong H, Chen H, Fu Y, et al. Secondary bacterial infections in critical ill patients with coronavirus disease 2019. Open Forum Infect Dis. 2020;7(6).

Hoque MN, Akter S, Mishu ID, Islam MR, Rahman MS, Akhter M, et al. Microbial co-infections in COVID-19: associated microbiota and underlying mechanisms of pathogenesis. Microb Pathogen. 2021;156:104941.

Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021:21(1):855.

Ho FK, Petermann-Rocha F, Gray SR, Jani BD, Katikireddi SV, Niedzwiedz CL, et al. Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants. PloS One. 2020;15(11):e0241824.

Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allerg Clin Immunol. 2020;146(1):110-8.

De Bruyn A, Verellen S, Bruckers L, Geebelen L, Callebaut I, De Pauw I, et al. Secondary infection in COVID-19 critically ill patients: a retrospective single-center evaluation. BMC Infect Dis. 2022;22(1):207.

MacIntyre CR, Chughtai AA, Barnes M, Ridda I, Seale H, Toms R, et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a (H1N1) pdm09. BMC Infect Dis. 2018;18:1-20.

Rawson TM, Moore LS, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;71(9):2459-68.

Baghdadi JD, Coffey KC, Adediran T, Goodman KE, Pineles L, Magder LS, et al. Antibiotic use and bacterial infection among inpatients in the first wave of COVID-19: a retrospective cohort study of 64,691 patients. Antimicrob Agents Chemother. 2021;65(11):10-128.

Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med. 2020;201(11):1380-8.

Shafran N, Shafran I, Ben-Zvi H, Sofer S, Sheena L, Krause I, et al. Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients. Sci Rep. 2021;11(1):12703.

Costa RL, Lamas CD, Simvoulidis LF, Espanha CA, Moreira LP, Bonancim RA, et al. Secondary infections in a cohort of patients with COVID-19 admitted to an intensive care unit: impact of gram-negative bacterial resistance. Revist Inst Med Trop São Paulo. 2022;64:e6.

Cusumano JA, Dupper AC, Malik Y, Gavioli EM, Banga J, Berbel Caban A, et al. Staphylococcus aureus bacteremia in patients infected with COVID-19: a case series. Open Forum Infect Dis. 2020;7(11):ofaa518.

Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2020;19(3):141-54.

Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.

Collier DA. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596(7872):417-22.

Ahamad MM. A machine learning model to identify early stage symptoms of SARS-Cov-2 infected patients. Exp Syst Appl. 2020;160:113661.

Tabernero E, Ruiz LA, España PP, Méndez R, Serrano L, Santos B, et al. COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences. Infection. 2022;50(1):179-89.

Mylene V, Peter J. The unrecognized threat of secondary bacterial infections with COVID-19. MBio. 2020:11(4).

Morris, DE, Cleary DW, Clarke SC. Secondary bacterial infections associated with influenza pandemics. Front Microbiol. 2017;8:1041.

Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198(7):962-70.

Louria DB, Blumenfeld HL, Ellis JT, Kilbourne ED, Rogers DE. Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. J Clin Invest. 1959:38(1):213-65.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.

Martinez-Guerra BA, Gonzalez-Lara MF, de-Leon-Cividanes NA, Tamez-Torres KM, Roman-Montes CM, Rajme-Lopez S, et al. Antimicrobial resistance patterns and antibiotic use during hospital conversion in the COVID-19 pandemic. Antibiotics. 2021;10(2):182.

Pourajam S, Kalantari E, Talebzadeh H, Mellali H, Sami R, Soltaninejad F, et al. Secondary bacterial infection and clinical characteristics in patients with COVID-19 admitted to two intensive care units of an academic hospital in Iran during the first wave of the pandemic. Front Cell Infect Microbiol. 2022;12:784130.

Juhi B, Donald RD, David AS. Tobacco use increases susceptibility to bacterial infection. Tob Induc Dis. 2008;4(1):12.